India’s BioEconomy Report (IBER) 2026: $195.3 Bn Milestone and Path to $300 Bn by 2030
India’s biotechnology sector has achieved a remarkable milestone, with its bioeconomy reaching $195.3 billion in 2025, growing at a record 18% year-on-year and contributing 4.8% to national GDP, as per the India BioEconomy Report (IBER) 2026 released by BIRAC on its 14th Foundation Day, March 19, 2026. From $10 billion in 2014, the sector has expanded nearly 20-fold, more than doubling since 2020, positioning India among the global top 12 biotech destinations.
Key Economic Metrics from IBER 2026
The report, highlighting BIRAC’s role in catalysing ₹4,200 crore funding for 15 lakh+ innovators, underscores accelerated momentum:
This 17.8–18% CAGR (2020–25) reflects resilience amid global challenges, driven by policy and innovation.
Sectoral Breakdown Driving Growth
The bioeconomy spans four pillars, with BioIndustrial leading:
- BioIndustrial ($90.2 Bn): Sustainable biomanufacturing, bio-chemicals, biofuels; largest segment.
- BioPharma ($64.5 Bn): Exports, biosimilars, peptides amid patent cliffs.
- BioServices ($26 Bn): 150+ GCCs employing 300,000+ in healthcare/life sciences.
- BioAgri ($14.6 Bn): Climate-resilient crops, bio-fertilizers, smart proteins.
Emerging areas like med-tech, health-tech, clean-tech amplify diversification.
Explosive Biotech Startup Ecosystem
India now boasts 11,855 biotech startups (up from prior years), with 1,780 new entries in 2025 (+15% YoY), increasingly from tier-2/3 cities. BIRAC’s BioNEST network (100+ incubators, 10.45 lakh sq ft) supports via grants, equity, mentoring, fostering 900+ products and 35,000 jobs.
Strategic Policy Drivers: BioE3 and RDI Fund
BioE3 Policy (Biotech for Economy, Environment, Employment)
- Focuses on high-performance biomanufacturing for green growth.
- Thousands of proposals in green chemicals, biofuels, and materials.
₹1 Lakh Crore RDI Fund (BIRAC Window)
- BIRAC manages ₹2,000 Cr initial tranche for TRL 4+ tech via equity/debt, bridging lab-to-market.
- Catalyses ₹7,000 Cr investments, scaling deep-tech.
These propel $300 Bn target by 2030.
UPSC Relevance: Science, Economy, Innovation
Prelims: BIRAC (DBT PSU), IBER 2026 ($195.3 Bn, 18% growth, 11,855 startups).
Mains (GS-3): Biotech as sunrise sector, Atmanirbhar, sustainable development, R&D policy. Links Panchamrit (biofuels), PLI (biosimilars).
Challenges: IP protection, funding gaps, regulatory streamlining—addressed via RDI/BioE3.
FAQs
Q1: What is the size of India's bioeconomy as per IBER 2026?
A: $195.3 billion in 2025, up 18% from $165.7 Bn (2024), contributing 4.8% to GDP.
Q2: When was IBER 2026 released?
A: March 19, 2026, on BIRAC's 14th Foundation Day.
Q3: How many biotech startups does India have?
A: 11,855 as of 2025, with 1,780 new in 2025 alone.
Q4: What is BioE3 Policy?
A: Biotechnology for Economy, Environment, Employment—promotes sustainable biomanufacturing.
Q5: What is the RDI Fund?
A: ₹1 lakh Cr fund; BIRAC manages ₹2,000 Cr for deep-tech biotech via equity/debt.
Q6: What is India's bioeconomy target?
A: $300 billion by 2030, building on 17.8% CAGR.
